NeuroLogica Corporation, a subsidiary of Samsung Electronics Co., Ltd.
$434.8K 550 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. reported $435,024.84 across General Payments, Research, and Ownership to 135 physicians and teaching hospitals across 135 transactions.
- $435.0K Above-median payer
- All-tracks total
- 135 Below-median volume
- Transactions
- 135 Below-median reach
- Recipients
- −$126.8K
- General Payments vs PY2023
Delphinus Medical Technologies, Inc. reported $435,024.84 across all CMS Open Payments tracks (General + Research + Ownership) to 135 physicians and teaching hospitals in Program Year 2024 - ranking #799 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $435,024.84, averaging $3.2K per recipient.
Delphinus Medical Technologies, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
15/100
Total payments
F
14/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer delphinus-medical-technologies-inc Delphinus Medical Technologies, Inc.
$435.0K · #799/1,925 · 0.0% industry · PY2024
- TOT $435.0K
- RANK #799
- SHARE 0.0%
- TXN 135
- RCP 135
- CAT 2
- GEN $435.0K
- ΔGEN −$126.8K
- TOP1 33.6%
- PY 2024
Volume peers
Nearest volume peer: NeuroLogica Corporation, a subsidiary of Samsung Electronics Co., Ltd. ($434.8K)
Delphinus Medical Technologies, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Delphinus Medical Technologies, Inc.'s CMS-reported General Payments decreased by $126.8K (−22.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: DELPHINUS MEDICAL TECHNOLOGIES, INC.PY2024: Delphinus Medical Technologies, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $561,854.69
- PY2024
- $435,024.84
What the Data Shows for Delphinus Medical Technologies, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Delphinus Medical Technologies, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $430.8K across 63 transactions, 99.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 2 types of general payments, Delphinus Medical Technologies, Inc.'s largest category was "Consulting Fee" at $430.8K - 99.0% of General Payments.
How Delphinus Medical Technologies, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $430.8K | 63 | 99.0% |
| Food and Beverage | $4.2K | 72 | 1.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $430,551.56 (99.0%) of $435,024.84 in this company's General Payments records across 26 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Delphinus Medical Technologies, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Peter Littrup
$146,000.16 across 24 reported transactions
- 2
Rachel Brem
$144,000.00 across 24 reported transactions
- 3
Mary Yamashita
$125,899.98 across 16 reported transactions
- 4
Vashita Dhir
$14,100.98 across 11 reported transactions
- 5
Arthy Saravanan
$550.44 across 7 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Delphinus Medical Technologies, Inc.'s spend rank (#799 of 1,925, top 42% by spend) and concentration rank (#558 of 1,838, top 30% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Merete Technologies, Inc : $72.1K total payments, HHI 3135
- Vifor (International) Ltd. : $132.0K total payments, HHI 3112
- Asklepios Biopharmaceutical Inc. : $7.6M total payments, HHI 3111
- Lumenis BE LTD : $35.5K total payments, HHI 3093
- Republic Spine : $567.3K total payments, HHI 3085
- Cook Research Incorporated : $288.6K total payments, HHI 3073
- Delphinus Medical Technologies, Inc. (this company) : $435.0K total payments, HHI 3070
- Perfuze Limited : $36.4K total payments, HHI 3056
- Medicaroid, Inc. : $3.1K total payments, HHI 3056
- Bard Access Systems, Inc. : $278.7K total payments, HHI 3052
- Den-Mat Holdings, LLC : $35.9K total payments, HHI 3047
- Maxx Health Inc : $11.5K total payments, HHI 3036
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Delphinus Medical Technologies, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Delphinus Medical Technologies, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Delphinus Medical Technologies, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Spectrum Pharmaceuticals Inc.
$434.4K 748 recipients
Compare payment profiles
Padagis US LLC
$436.5K 0 recipients
Compare payment profiles
PhotoniCare Inc
$437.5K 200 recipients
Compare payment profiles
Caption Health, Inc.
$438.6K 2 recipients
Compare payment profiles
RedDress LTD
$439.2K 0 recipients
Compare payment profiles
Put this to use
Delphinus Medical Technologies, Inc. ranks #799 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Delphinus Medical Technologies, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.